Skip to main content
NextGen MedPrep logoNextGenMedPrep
Back to Medical School Compare
Medical school comparison

Queen's University Belfast (QUB) vs University of Central Lancashire (UCLan)

Queen's University Belfast (QUB) and University of Central Lancashire (UCLan) are both UK medical schools, but the path to an offer at each is meaningfully different. Queen's University Belfast (QUB) is based in Belfast (Northern Ireland) while University of Central Lancashire (UCLan) sits in Preston (England), and the regional context shapes everything from fee status to NHS-deanery destination. Their A-Level requirements (AAA vs AAB) place them in slightly different academic-strictness tiers. Queen's University Belfast (QUB) is the older institution (founded 1849); the other (founded 2014) has shaped its medical school around modern integrated-curriculum thinking.

Side-by-side comparison

Queen's University Belfast (QUB)

Belfast

Quick comparison

Location
Belfast, UK
A-Level offer
A*AA at A-level including Chemistry and Biology (or Maths/Physics - see subject rules)
TrueScore
1700
UCAT home cut-off
~1700+ /2700 with 9× grade 9s GCSE (~35/45 target). Lower UCAT viable with stronger GCSE.
Interview format
Multiple Mini Interviews (MMI)
Post-interview chance
Home: 332/778 = 43%; International: 51/214 = 24%
Decision date
April onwards

University of Central Lancashire (UCLan)

Preston

Quick comparison

Location
Preston, UK
A-Level offer
AAB at A-level including Biology and Chemistry (home applicants)
TrueScore
-
UCAT home cut-off
UCAT used for home applicant shortlisting; no published cut-off
Interview format
Multiple Mini Interviews (MMI)
Post-interview chance
-
Decision date
March - April
Compare different schools

Queen's University Belfast (QUB) vs University of Central Lancashire (UCLan) - in detail

A-Level and academic profile

Queen's University Belfast (QUB) requires AAA including Chemistry and Biology. University of Central Lancashire (UCLan) requires AAB at A-level including Biology and Chemistry (home applicants). Queen's University Belfast (QUB) is the stricter A-Level offer; University of Central Lancashire (UCLan) is slightly more forgiving. If your predicted grades are borderline, University of Central Lancashire (UCLan) carries the lower academic-rejection risk pre-interview.

Interview formats

Both Queen's University Belfast (QUB) and University of Central Lancashire (UCLan) use MMI interviews, so the underlying prep approach is the same — practise ethics frameworks, NHS hot-topic answers and (for MMI) structured station responses against a timer. Interview windows: Queen's University Belfast (QUB) interviews in January - February; University of Central Lancashire (UCLan) in December - February.

What makes each distinctive

Queen's University Belfast (QUB): Less weight on NHS hot topics than most schools. Stronger emphasis on reflective examples of personal qualities. SJT may be used if borderline before or after interview, but in 2025 anyone with 30/42 received an interview regardless. University of Central Lancashire (UCLan): One of the first UK universities to run a privately-funded medical school open to international students; substantial international cohort blended with a smaller home intake. Strong Lancashire regional placement network.

Which is right for you?

For applicants with predicted A-Level grades at the lower end of the AAA-A*AA range, University of Central Lancashire (UCLan) is the lower-risk academic option. Regionally, the choice often comes down to cost of living and NHS-deanery preferences — Queen's University Belfast (QUB) feeds into the Northern Ireland foundation programme network; University of Central Lancashire (UCLan) into the England network. Your firm/insurance choice should ultimately weight: where your UCAT and predicted grades sit relative to each school's threshold, which interview format you can prepare for most credibly, and where you'd actually want to live for five or six years.

Common questions

School data reviewed by the NextGen MedPrep editorial team — last reviewed 3 July 2026.